Year: 2019

APB „Apranga“ gavo pranešimą apie su valdybos pirmininku Darium Mockum glaudžiai susijusio juridinio asmens UAB „Minvista“ sandorius dėl emitento vertybinių popierių (žr. prisegtą bylą).Saulius Bačauskas„Aprangos“ grupės finansų ir ekonomikos direktorius(8-5) 2390843PriedasPranesimas apie emitento vadovu sandorius 2019-12-13

December 13, 2019Following the announcement on December 11, 2019, with respect to the contract signature for FPSO Sepetiba, SBM Offshore is pleased to announce that it has entered into a shareholder agreement with its long standing business partners Mitsubishi Corporation (MC) and Nippon Yusen Kabushiki Kaisha (NYK) regarding the divestment of a 35.5% interest in the special purpose companies related to the lease and operation of FPSO Sepetiba.MC acquired 20% and NYK acquired 15.5% ownership interest in the companies. SBM Offshore is operator and majority shareholder with the remaining 64.5% ownership interest.FPSO Sepetiba is currently under construction. The FPSO will be deployed at the Mero field in the Santos Basin offshore Brazil, 180 kilometers offshore Rio de Janeiro, under a 22.5 years lease and operate contract with Petróleo...

Ovaro Kiinteistösijoitus Oyj Muutokset omien osakkeiden omistuksessa Pörssitiedote 13.12.2019 klo 08.30 Ovaro on saanut päätökseen omien osakkeidensa hankinnan Ovaro on saanut päätökseen omien osakkeidensa hankinnan, joka alkoi 18.11.2019 ja päättyi 12.12.2019. Tänä aikana Ovaro hankki 40.000 omaa osaketta keskihintaan 4,2147 euroa osakkeelta. Osakkeet hankittiin Nasdaq Helsinki Oy:n järjestämässä julkisessa kaupankäynnissä hankintahetken markkinahintaan.Osakkeiden hankinta perustui varsinaisen yhtiökokouksen 13.3.2019 yhtiön hallitukselle antamaan valtuutukseen enintään 900.000 oman osakkeen hankkimisesta ja hallituksen 7.8.2019 tekemään päätökseen 160.000 osakkeen osto-ohjelmasta ajalla 12.8. – 14.10.2019.Hankinnan jälkeen Ovaro Kiinteistösijoitus Oyj:llä on yhteensä 287.016 omaa osaketta, jotka vastaavat n. 2,99 prosenttia yhtiön kaikista...

Nasdaq First North Growth MarketPostbox 1007Nikolaj Plads 61040 København KSELSKABSMEDDELELSEMÅ IKKE OFFENTLIGGØRES, DISTRIBUERES ELLER UDLEVERES HELT ELLER DELVIST, DIREKTE ELLER INDIREKTE, TIL USA, AUSTRALIEN, CANADA ELLER JAPAN.Selskabsmeddelelse nr. 11 – 13-12-2019                                           Odense, 13. december 2019ESA og NASAs panel for fremtidigt motionsudstyr anbefaler enstemmigt DAC’s E4D-udstyr til kommende bemandede rejser ud i rummet.NASA og ESAs ”Exploration Exercise Device Downselect” (EEDD) panel har evalueret Danish Aerospace Company A/S’ (DAC) E4D-motionsudstyr op mod et andet amerikansk udstyr, for at kunne anbefale, hvilket man skal arbejde videre med til fremtidige bemandede rejser til Månen og længere ud i rummet. EEDD-panelet bestod af 7 eksperter fra NASA og 3 eksperter fra ESA.EEDD-panelet har enstemmig...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102, a potentially first-in-class anti-KIR3DL2 antibody).  The Company will take the following actions based on ongoing discussions with regulatory authorities regarding a quality issue related to the chemistry, manufacturing and controls (CMC) process: Lacutumab will not be administered to new patients in the TELLOMAK trial until additional feedback is received from the respective regulatory agencies overseeing our clinical trial.Until further notice, the Company will continue to treat patients who are currently enrolled in the multi-center trial, except in Italy where the clinical trial has been suspended due to the feedback...

Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé une mise à jour concernant son essai TELLOMAK de Phase II évaluant l’efficacité et la sécurité de lacutamab (IPH4102, un anticorps anti-KIR3DL2 potentiellement « first-in-class »). La Société va mettre en œuvre les actions suivantes à la suite de discussions en cours avec les autorités réglementaires au sujet d’un problème de qualité dans le processus de développement pharmaceutique :Dans l’attente du retour additionnel des autorités réglementaires respectives supervisant nos essais cliniques, lacutamab ne sera pas administré à de nouveaux patients.Jusqu’à nouvel ordre, la Société continuera de traiter les patients déjà recrutés dans cet essai multicentrique, hormis en Italie où l’essai est suspendu à la suite du retour...

VANCOUVER, British Columbia, Dec. 12, 2019 (GLOBE NEWSWIRE) — Western Forest Products Inc. (TSX: WEF) (“Western” or the “Company”) announced today that independent mediators Vince Ready and Amanda Rogers today informed the Company and the United Steelworkers Local 1-1937 (“USW”) that due to personal circumstances, meetings between the parties will resume next week. The parties have agreed to a media blackout during this mediation process.The strike, which commenced on July 1, 2019, affects all the Company’s USW certified manufacturing and timberlands operations in British Columbia, impacting approximately 1,500 of the Company’s hourly employees and approximately 1,500 employees working for the Company’s timberland operations and contractors.About Western Forest Products Inc.Western is an integrated forest products company building...

CHICAGO, Dec. 12, 2019 (GLOBE NEWSWIRE) — Sprout Social, Inc. (“Sprout Social” or the “Company”) announced today the pricing of its initial public offering of 8,823,530 shares of Class A common stock at a price to the public of $17.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Capital Market on December 13, 2019 under the ticker symbol “SPT.” The offering is expected to close on December 17, 2019, subject to the satisfaction of customary closing conditions.Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC are serving as lead book-running managers for the offering. KeyBanc...

WARREN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (Nasdaq:AQST) (“Aquestive”), a specialty pharmaceutical company focused on developing and commercializing differentiated products to meet patients’ unmet needs and solve therapeutic problems, today announced the pricing of its public offering of 7,000,000 shares of common stock at a public offering price of $5.00 per share for aggregate gross proceeds of $35.0 million. All of the shares in the offering are being offered by Aquestive. In addition, Aquestive granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about on December 17, 2019, subject to the satisfaction of customary closing conditions.BMO Capital...

BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) — The New Ireland Fund, Inc. (NYSE: IRL) (the “Fund”), a closed-end fund, today announced that its Board of Directors (the “Board”) determined that it is in the best interest of the Fund and its stockholders to suspend the Fund’s managed distribution policy (the “Policy”).  The suspension of the Policy does not impact the Fund’s investment objective of long-term capital appreciation through investment primarily in equity securities of Irish companies.  The Fund will distribute to shareholders, at least annually, substantially all of its net income from dividends and interest payments and expects to distribute substantially all of its net realized capital gains annually. During the regular review of the Policy by the Board, among other things, the Board considered the Policy’s potential to increase...